Drug contractor Catalent plunges after annual guidance cut, results delayed
After a 28% share price drop following a downgrade and postponement of the contract research organization’s Q3 report, Catalent is now trading at its lowest in three years.
By Ilena Peng, bloomberg
Catalent Inc. shares traded at their lowest in three years following cuts to its annual financial outlook that hurt investor confidence in the contract drug manufacturer.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Danaher shelves its takeover pursuit of Catalent
For subscribers
Danaher takes interest in Catalent
For subscribers
